Stock comparison
Bio-Rad Laboratories
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIO
Bio-Rad Laboratories
Market cap
$7.78B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIO | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 77B | LMAT |
| Benjamin Graham | 48D | 89A | LMAT |
| Philip Fisher | 30F | 81C | LMAT |
| Peter Lynch | 10F | 67B | LMAT |
| Joel Greenblatt | 42D | 56D | LMAT |
| Charlie Munger | 34F | 68D | LMAT |
| Terry Smith | 26F | 69D | LMAT |
Side-by-side metrics
| Metric | BIO | LMAT |
|---|---|---|
| Market cap | $7.78B | $2.23B |
| P/E (TTM) | 39.5x | 37.1x |
| EV/EBIT | 28.0x | 36.6x |
| ROIC (TTM) | 1.95% | 9.43% |
| Gross margin | 51.87% | 72.39% |
| Net margin | 6.52% | 24.35% |
| Revenue CAGR 5y | -3.04% | 12.75% |
| EPS CAGR 5y | -33.51% | 19.04% |
| Debt / Equity | 0.2x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIO leads on
- Market cap$7.78Bvs $2.23B+71%
- Debt / Equity0.2xvs 0.5x+57%
- EV/EBIT28.0xvs 36.6x+24%
LMAT leads on
- EPS CAGR 5y19.04%vs -33.51%+157%
- Revenue CAGR 5y12.75%vs -3.04%+124%
- Dividend yield0.84%vs 0.0%+100%
- ROIC (TTM)9.43%vs 1.95%+79%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.